Logo image of INSM

INSMED INC (INSM) Stock Fundamental Analysis

USA - NASDAQ:INSM - US4576693075 - Common Stock

165.76 USD
+2.57 (+1.57%)
Last: 10/17/2025, 5:25:21 PM
165.76 USD
0 (0%)
After Hours: 10/17/2025, 5:25:21 PM
Fundamental Rating

4

INSM gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. INSM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INSM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year INSM has reported negative net income.
INSM had a negative operating cash flow in the past year.
INSM had negative earnings in each of the past 5 years.
In the past 5 years INSM always reported negative operating cash flow.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

With a Return On Assets value of -41.71%, INSM perfoms like the industry average, outperforming 58.02% of the companies in the same industry.
The Return On Equity of INSM (-82.76%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -41.71%
ROE -82.76%
ROIC N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

INSM's Gross Margin of 75.72% is amongst the best of the industry. INSM outperforms 83.77% of its industry peers.
In the last couple of years the Gross Margin of INSM has remained more or less at the same level.
INSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INSM has more shares outstanding
The number of shares outstanding for INSM has been increased compared to 5 years ago.
INSM has a better debt/assets ratio than last year.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 13.82 indicates that INSM is not in any danger for bankruptcy at the moment.
INSM has a Altman-Z score of 13.82. This is amongst the best in the industry. INSM outperforms 86.57% of its industry peers.
INSM has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
INSM has a Debt to Equity ratio of 0.45. This is in the lower half of the industry: INSM underperforms 71.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 13.82
ROIC/WACCN/A
WACC9.25%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 6.68 indicates that INSM has no problem at all paying its short term obligations.
INSM has a Current ratio of 6.68. This is in the better half of the industry: INSM outperforms 67.16% of its industry peers.
INSM has a Quick Ratio of 6.33. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of INSM (6.33) is better than 66.04% of its industry peers.
Industry RankSector Rank
Current Ratio 6.68
Quick Ratio 6.33
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for INSM have decreased by -5.94% in the last year.
Looking at the last year, INSM shows a very strong growth in Revenue. The Revenue has grown by 21.15%.
The Revenue has been growing by 21.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-5.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.37%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%18.9%

3.2 Future

INSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.72% yearly.
Based on estimates for the next years, INSM will show a very strong growth in Revenue. The Revenue will grow by 66.51% on average per year.
EPS Next Y-0.54%
EPS Next 2Y13.25%
EPS Next 3Y20.49%
EPS Next 5Y28.72%
Revenue Next Year30.36%
Revenue Next 2Y70.88%
Revenue Next 3Y77.17%
Revenue Next 5Y66.51%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B 8B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INSM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as INSM's earnings are expected to grow with 20.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.25%
EPS Next 3Y20.49%

More info and screens

0

5. Dividend

5.1 Amount

INSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INSMED INC

NASDAQ:INSM (10/17/2025, 5:25:21 PM)

After market: 165.76 0 (0%)

165.76

+2.57 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-29 2025-10-29
Inst Owners99.73%
Inst Owner Change-0.06%
Ins Owners0.67%
Ins Owner Change-11.14%
Market Cap35.04B
Analysts85.38
Price Target156.83 (-5.39%)
Short Float %5.06%
Short Ratio4.13
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.66%
Min EPS beat(2)-28.87%
Max EPS beat(2)-4.46%
EPS beat(4)0
Avg EPS beat(4)-11.73%
Min EPS beat(4)-28.87%
Max EPS beat(4)-2.38%
EPS beat(8)2
Avg EPS beat(8)-10.89%
EPS beat(12)2
Avg EPS beat(12)-14.95%
EPS beat(16)4
Avg EPS beat(16)-10.08%
Revenue beat(2)1
Avg Revenue beat(2)0.13%
Min Revenue beat(2)-1.17%
Max Revenue beat(2)1.43%
Revenue beat(4)1
Avg Revenue beat(4)-0.42%
Min Revenue beat(4)-1.53%
Max Revenue beat(4)1.43%
Revenue beat(8)2
Avg Revenue beat(8)-1.08%
Revenue beat(12)3
Avg Revenue beat(12)-0.69%
Revenue beat(16)5
Avg Revenue beat(16)-0.1%
PT rev (1m)6.87%
PT rev (3m)37.64%
EPS NQ rev (1m)0.67%
EPS NQ rev (3m)0.33%
EPS NY rev (1m)-0.44%
EPS NY rev (3m)-4.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0.38%
Revenue NY rev (3m)3.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 88.01
P/FCF N/A
P/OCF N/A
P/B 28.04
P/tB 33.13
EV/EBITDA N/A
EPS(TTM)-5.71
EYN/A
EPS(NY)-4.01
Fwd EYN/A
FCF(TTM)-4.11
FCFYN/A
OCF(TTM)-4
OCFYN/A
SpS1.88
BVpS5.91
TBVpS5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41.71%
ROE -82.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.72%
FCFM N/A
ROA(3y)-43.52%
ROA(5y)-40.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.05%
GM growth 5Y-1.46%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 159.38%
Cap/Sales 6.03%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.68
Quick Ratio 6.33
Altman-Z 13.82
F-Score4
WACC9.25%
ROIC/WACCN/A
Cap/Depr(3y)113.37%
Cap/Depr(5y)86.53%
Cap/Sales(3y)4.8%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.37%
EPS Next Y-0.54%
EPS Next 2Y13.25%
EPS Next 3Y20.49%
EPS Next 5Y28.72%
Revenue 1Y (TTM)21.15%
Revenue growth 3Y24.49%
Revenue growth 5Y21.65%
Sales Q2Q%18.9%
Revenue Next Year30.36%
Revenue Next 2Y70.88%
Revenue Next 3Y77.17%
Revenue Next 5Y66.51%
EBIT growth 1Y-44.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.85%
EBIT Next 3Y24.22%
EBIT Next 5YN/A
FCF growth 1Y-82.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-82.77%
OCF growth 3YN/A
OCF growth 5YN/A